SAVARINO, VINCENZO
 Distribuzione geografica
Continente #
EU - Europa 51.314
AS - Asia 1.512
SA - Sud America 268
NA - Nord America 191
AF - Africa 41
Totale 53.326
Nazione #
IT - Italia 51.247
SG - Singapore 638
CN - Cina 442
VN - Vietnam 283
BR - Brasile 177
US - Stati Uniti d'America 131
HK - Hong Kong 51
AR - Argentina 48
MX - Messico 44
IN - India 18
EC - Ecuador 17
ID - Indonesia 15
IQ - Iraq 15
GB - Regno Unito 14
BD - Bangladesh 12
CA - Canada 12
RU - Federazione Russa 9
ZA - Sudafrica 8
ES - Italia 7
KE - Kenya 7
PL - Polonia 7
VE - Venezuela 7
CL - Cile 6
DE - Germania 6
NL - Olanda 6
CO - Colombia 4
MA - Marocco 4
NP - Nepal 4
PE - Perù 4
BY - Bielorussia 3
DZ - Algeria 3
JO - Giordania 3
JP - Giappone 3
LT - Lituania 3
PY - Paraguay 3
SN - Senegal 3
TR - Turchia 3
AZ - Azerbaigian 2
BH - Bahrain 2
EG - Egitto 2
IR - Iran 2
KH - Cambogia 2
LK - Sri Lanka 2
MN - Mongolia 2
MY - Malesia 2
NG - Nigeria 2
PK - Pakistan 2
SE - Svezia 2
TG - Togo 2
UY - Uruguay 2
AE - Emirati Arabi Uniti 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
BW - Botswana 1
CG - Congo 1
CH - Svizzera 1
CI - Costa d'Avorio 1
CR - Costa Rica 1
CY - Cipro 1
DO - Repubblica Dominicana 1
FI - Finlandia 1
FR - Francia 1
GA - Gabon 1
IE - Irlanda 1
IL - Israele 1
KG - Kirghizistan 1
KZ - Kazakistan 1
LY - Libia 1
ME - Montenegro 1
MK - Macedonia 1
NA - Namibia 1
NI - Nicaragua 1
PA - Panama 1
PH - Filippine 1
PS - Palestinian Territory 1
SI - Slovenia 1
SY - Repubblica araba siriana 1
TH - Thailandia 1
TN - Tunisia 1
TZ - Tanzania 1
UA - Ucraina 1
UG - Uganda 1
YT - Mayotte 1
Totale 53.326
Città #
Genova 33.728
Genoa 10.449
Rapallo 4.096
Vado Ligure 2.886
Singapore 310
Beijing 118
Ho Chi Minh City 105
Hanoi 70
Bordighera 62
Hong Kong 51
Ashburn 47
Mexico City 32
Tianjin 23
Da Nang 14
Orem 14
São Paulo 14
Los Angeles 11
New York 11
Haiphong 10
Bologna 8
Hải Dương 8
Ninh Bình 8
Rio de Janeiro 8
Baghdad 7
Chennai 7
Montreal 7
Quito 7
Warsaw 7
Nairobi 6
Poplar 6
Quảng Ngãi 6
Biên Hòa 5
Fortaleza 5
Guangzhou 5
Guayaquil 5
Curitiba 4
Moscow 4
Mumbai 4
Orangeburg 4
Querétaro 4
Rome 4
San Jose 4
Amman 3
Amsterdam 3
Brasília 3
Buenos Aires 3
Bắc Ninh 3
Changsha 3
Chicago 3
Dakar 3
Formosa 3
Manchester 3
Manta 3
Milan 3
Minsk 3
Montes Claros 3
Thái Bình 3
Thái Nguyên 3
Tokyo 3
Toronto 3
Ankara 2
Atibaia 2
Bandung 2
Bauru 2
Boston 2
Brooklyn 2
Bắc Giang 2
Camaçari 2
Campos dos Goytacazes 2
Cape Town 2
Cleveland 2
Colombo 2
Dhaka 2
Florianópolis 2
Frankfurt am Main 2
Guarapuava 2
Hanau 2
Heshan 2
Houston 2
Hyderabad 2
Isidro Casanova 2
Ituzaingó 2
Johannesburg 2
Kuala Lumpur 2
Lagos 2
Las Rosas 2
Lima 2
Lomas de Zamora 2
Lomé 2
London 2
Manama 2
Manaus 2
Maracaibo 2
Mariano Moreno 2
Mediglia 2
Montevideo 2
Mosul 2
Naples 2
Nha Trang 2
Nuremberg 2
Totale 52.318
Nome #
Hepatobiliary and Pancreatic: A rare cause of portal hypertension. 231
Proton pump inhibitors: use and misuse in the clinical setting 199
5-ASA and colorectal cancer chemoprevention in inflammatory bowel disease: can we afford to wait for “best evidence”? 198
Time pattern of gastric acidity in Barrett's esophagus 191
A pharmacodynamic study of two omeprazole regimens suitable for long-term treatment of duodenal ulcer. 190
Contribution of germline mutations in the BRCA and PALB2 genes to pancreatic cancer in Italy. 187
CDKN2A is the main susceptibility gene in Italian pancreatic cancer families. 187
Positive PET in a patient with esophageal leiomyoma. 187
13C-mixed triglyceride (13C-MTG) breath-test (BT) in Cystic Fibrosis (CF). 186
Not All Patients With Non-erosive Reflux Disease Share Psychological Distress as Main Mechanism of Disease. 184
Circadian pattern of intragastric acidity in patients with non-erosive reflux disease (NERD) 183
Reassessment of the diagnostic value of histology in patients with GERD, using multiple biopsy sites and an appropriate control group 182
Circadian monitoring of gastric juice mutagenicity. 181
Anti-TNF therapy is able to stabilize bowel damage progression in patients with Crohn's disease. A study performed using the Lémann Index 179
Outcome of nonerosive gastro-esophageal reflux disease patients with pathological acid exposure. 177
Alginate controls heartburn in patients with erosive and nonerosive reflux disease. 177
A comparison of the effects on intragastric acidity of bedtime or dinnertime administration of a once daily dose of famotidine. 176
Germline MLH1 and MSH2 mutations in Italian pancreatic cancer patients with suspected Lynch syndrome. 176
Are proton pump inhibitors really so dangerous? 176
A safety review of proton pump inhibitors to treat acid-related digestive diseases 176
A review of pharmacotherapy for treating gastroesophageal reflux disease (GERD) 175
Measurement of sorafenib plasma concentration by high-performance liquid chromatography in patients with advanced hepatocellular carcinoma: is it useful the application in clinical practice? A pilot study 173
Barrett's esophagus in 2016: From pathophysiology to treatment 173
Pathophysiology, diagnosis, and pharmacological treatment of gastro-esophageal reflux disease 173
A comparison between sodium alginate and magaldrate anhydrous in the treatment of patients with gastroesophageal reflux symptoms. 172
A study of 4-and 7-day triple therapy with rabeprazole, high-dose levofloxacin and tinidazole rescue treatment for Helicobacter pylori eradication 172
Vigor of peristalsis during multiple rapid swallows is inversely correlated with acid exposure time in patients with NERD 171
Alpha-fetoprotein has no prognostic role in small hepatocellular carcinoma identified during surveillance in compensated cirrhosis. 170
Breath tests to assess alcoholic liver disease. 170
Application of the platelet count/spleen diameter ratio to rule out the presence of oesophageal varices in patients with cirrhosis: a validation study based on follow-up 169
Measurement of oro-caecal transit time by magnetic resonance imaging. 167
Comparative effects of levosulpiride and cisapride on gastric emptying and symptoms in patients with functional dyspepsia and gastroparesis 166
Peripheral blood cytopaenia limiting initiation of treatment in chronic hepatitis C patients otherwise eligible for antiviral therapy 165
A new 1-week therapy for Helicobacter pylori eradication: ranitidine bismuth citrate plus two antibiotics. 165
Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. 165
Association Between Baseline Impedance Values and Response Proton Pump Inhibitors in Patients With Heartburn 165
Ilaprazole for the treatment of gastro-esophageal reflux 165
Barcelona Clinic Liver Cancer staging and transplant survival benefit for patients with hepatocellular carcinoma: a multicentre, cohort study. 164
Improvement in esophageal motor abnormalities in systemic sclerosis patients treated with cyclosporine: comment on the article by Clements et al. 164
Drugs for improving esophageal mucosa defense: Where are we now and where are we going? 164
High anti-TNF alfa drugs trough levels are not associated with the occurrence of adverse events in patients with inflammatory bowel disease 164
24-hour gastric pH and extent of duodenal gastric metaplasia in Helicobacter pylori-positive patients. 163
Circadian reduction of chromium in the gastric environment. 163
24-hour study of intragastric acidity in duodenal ulcer patients and normal subjects using continuous intraluminal pH-metry. 162
A Comparison Between Lactose Breath Test and Quick Test on Duodenal Biopsies for Diagnosing Lactase Deficiency in Patients With Self-reported Lactose Intolerance. 162
Influence of clinically significant portal hypertension on survival after hepatic resection for hepatocellular carcinoma in cirrhotic patients. 162
Can artificial neural networks be beneficial in diagnosing gastro-oesophageal reflux disease? 162
Are duodenal ulcer seasonal fluctuations paralleled by seasonal changes in 24-hour gastric acidity and Helicobacter pylori infection? 161
An evaluation of the antireflux properties of sodium alginate by means of combined multichannel intraluminal impedance and pH-metry. 160
Microscopic esophagitis distinguishes patients with non-erosive reflux disease from those with functional heartburn. 160
Burden of illness in Italian patients with gastro-oesophageal reflux disease. 159
Clinical trial: the combination of rifaximin with partially hydrolysed guar gum is more effective than rifaximin alone in eradicating small intestinal bacterial overgrowth. 159
A comparison of five maintenance therapies for reflux esophagitis 159
Narrow-band imaging with magnifying endoscopy is accurate for detecting gastric intestinal metaplasia. 159
A 10-day levofloxacin-based therapy in patients with resistant Helicobacter pylori infection: a controlled trial 159
Oesophageal motility and bolus transit abnormalities increase in parallel with the severity of gastro-oesophageal reflux disease. 159
Lower pH values of weakly acidic refluxes as determinants of heartburn perception in gastroesophageal reflux disease patients with normal esophageal acid exposure 158
24-H comparison between pH values of continuous intraluminal recording and simultaneous gastric aspiration. 158
Acid and gastric metaplasia in the duodenum 156
Impact of evidence-based medicine on treatment of patients with unresectable hepatocellular carcinoma 155
Antimony and glass pH electrodes can be used interchangeably in 24-hour studies of gastric acidity. 155
Antisecretory effects of three omeprazole regimens for maintenance treatment in duodenal ulcer. 155
Adalimumab trough serum levels and anti-adalimumab antibodies in the long-term clinical outcome of patients with Crohn’s disease. 155
A Nodule, is a Nodule, is a Nodule: May Alpha-fetoprotein Make the Difference? 155
Anti-TNF Antibodies For Prevention of Crohn's Disease Recurrence After Surgery: More Than An Hope. 155
Absence of tolerance in duodenal ulcer patients treated for 28 days with a bedtime dose of roxatidine or ranitidine. 154
Starry Liver: An Unexpected Diagnosis 153
Comparison of Two Different Techniques to Assess Adalimumab Trough Levels in Patients with Crohn's Disease. 153
Analyses of the Post-reflux Swallow-induced Peristaltic Wave Index and Nocturnal Baseline Impedance Parameters Increase the Diagnostic Yield of Patients With Reflux Disease 153
Impedance-pH reflux patterns can differentiate non-erosive reflux disease from functional heartburn patients. 153
Adalimumab trough levels and response to biological treatment in patients with Inflammatory Bowel Disease: a useful cut-off In clinical practice. 152
New insight in the mechanism of omeprazole antimicrobial combinations to eradicate Helicobacter pylori. 150
The role of small intestinal bacterial overgrowth in rosacea: A 3-year follow-up 150
An independent validation of the mortality score for the short-term prognostic prediction in patients with chronic hepatitis C virus infection and advanced liver disease 149
Successful antiviral therapy determines a significant decrease in squamous cell carcinoma antigen-associated (SCCA) variants' serum levels in anti-HCV positive cirrhotic patients. 149
Low serum trough levels are associated with post-surgical recurrence in Crohn's disease patients undergoing prophylaxis with adalimumab. 149
External Validation of the Platelet Count/Spleen Diameter Ratio for the Diagnosis of Esophageal Varices in Hepatitis C Virus-Related Cirrhosis 148
Once and twice daily doses of H2 antagonists revisited, using continuous intragastric pH monitoring. 148
Comparison between laparoscopy, ultrasonography, and computed tomography in widespread and localized liver diseases. 148
Letter: Biologics are effective in neutralising the detrimental effect of smoking on the natural course of Crohn's disease 148
Reduction in TIMP-2 serum levels predicts remission of inflammatory bowel diseases 148
Hepatocellular carcinoma in patients with cryptogenic cirrhosis 147
Blessed are those who have not seen and yet have believed 147
Circadian acidity pattern in prepyloric ulcers: a comparison with normal subjects and duodenal ulcer patients. 147
NERD: an umbrella term including heterogeneous subpopulations. 147
OAM for cure of Helicobacter pylori infection. 146
Microscopic Esophagitis is More Frequent in Patients With pH-Positive Non-Erosive Reflux Disease and Hypersensitive Esophagus Than in Those With Functional Heartburn: A Study Using Impedance-pH and Optical Microscopy. 146
Infliximab trough levels and persistent vs transient antibodies measured early after induction predict long-term clinical remission in patients with inflammatory bowel disease 146
Low bedtime doses of H2-receptor antagonists for acute treatment of duodenal ulcer. 145
Nevoid Basal Cell Carcinoma Syndrome in infants: improving diagnosis. 144
Circadian gastric acidity in Helicobacter pylori positive ulcer patients with and without gastric metaplasia in the duodenum. 144
Anti-helicobacter regimens 143
Assessment of Intestinal Permeability Using Sugar Probes: Influence of Urinary Volume 143
Impact of E27X, a novel CDKN2A germ line mutation, on p16 and p14ARF expression in Italian melanoma families displaying pancreatic cancer and neuroblastoma. 143
Effective intra-oesophageal acid suppression in patients with gastro-oesophageal reflux disease: lansoprazole vs pantoprazole. 142
Influence of Helicobacter pylori eradication therapy on 13C aminopyrine breath test: comparison among omeprazole-, lansoprazole-, or pantoprazole-containing regimens 142
Improvement in Waldenstrom’s macroglobulinemia after successful treatment of HCV with direct-acting antivirals 141
Discriminant value of dyspepsia subgroups. 140
Prevalence of the E318K MITF germline mutation in Italian melanoma patients: associations with histological subtypes and family cancer history. 140
Quality of life in acute and maintenance treatment of non-erosive and mild erosive gastro-oesophageal reflux disease. 139
Totale 16.203
Categoria #
all - tutte 167.254
article - articoli 155.803
book - libri 462
conference - conferenze 2.421
curatela - curatele 0
other - altro 8.292
patent - brevetti 0
selected - selezionate 0
volume - volumi 276
Totale 334.508


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.901 0 0 0 0 0 294 123 332 317 354 224 257
2021/20225.241 161 297 378 744 235 408 388 1.125 212 497 177 619
2022/20234.913 530 265 60 424 947 890 6 379 886 32 437 57
2023/20242.217 117 319 50 224 185 396 129 100 138 39 142 378
2024/20257.016 275 599 263 452 959 718 570 1.066 279 293 695 847
2025/20265.541 1.420 298 927 1.117 1.408 371 0 0 0 0 0 0
Totale 53.942